头颈癌质子治疗中的急性毒性——DAHANCA 35 可行性研究的匹配分析
作为比较质子放疗与光子放疗的全国随机研究 DAHANCA 35 的准备,开展非随机先导研究,将 62 例质子治疗患者与 124 例协议外光子治疗患者按治疗中心、同步化疗、肿瘤部位、分期及口咽癌 p16 状态匹配。质子组治疗结束时体重减轻均值 3% 低于光子组 5%(p < 0.001),但 3 级皮肤反应 RR 1.9(95%CI 1.01-3.5,p=0.04)和 3 级黏膜炎 RR 1.5(95%CI 1.3-1.7,p < 0.001)多于光子组,上述差异在治疗后两个月随访时均消失。
要点
- 质子组治疗结束时体重减轻均值 3%,光子组 5%(p < 0.001)。
- 质子组 3 级皮肤反应 RR 1.9(95%CI 1.01-3.5,p=0.04),3 级黏膜炎 RR 1.5(95%CI 1.3-1.7,p < 0.001)。
- 上述毒性差异在治疗后两个月随访时均消失。
核心结论
- 质子治疗导致过多的客观黏膜炎和皮炎,但为暂时性,似乎未对体重、治疗依从性和治疗强度产生负面影响。
- 选择偏倚可能存在,尤其是因为 NTCP 模型用于选择质子治疗且光子治疗患者为手动匹配。
- 目前正在随机对照试验中纳入患者。
研究设计与样本
- 非随机先导研究,作为比较质子放疗与光子放疗的全国随机研究 DAHANCA 35 的准备。
- 62 例质子治疗患者与 124 例协议外光子治疗患者匹配,数据取自 DAHANCA 数据库。
- 匹配因素为治疗中心、同步化疗、肿瘤部位、分期、口咽癌 p16 状态。
- 质子治疗患者选择基于比较治疗计划,要求六个月时吞咽困难和口干症的 NTCP 降低。
主要发现
- 两组基线特征均衡良好,但同步药物类型不同,光子组更多患者接受卡铂(21.2% vs 5.8%,p=0.01)。
- 质子组治疗结束时体重减轻均值 3%,光子组 5%(p < 0.001)。
- 质子组治疗结束时 3 级皮肤反应多于光子组,RR 1.9(95%CI 1.01-3.5,p=0.04)。
- 质子组治疗结束时 3 级黏膜炎多于光子组,RR 1.5(95%CI 1.3-1.7,p < 0.001)。
- 上述所有差异在治疗后两个月随访时均消失;观察期间两组在阿片类药物使用、喂养管使用或住院方面无显著差异。
临床怎么用
- 原文未据此给出推荐。
局限性
- 选择偏倚可能存在,尤其是因为 NTCP 模型用于选择质子治疗且光子治疗患者为手动匹配。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND PURPOSE: As preparation for a national randomized study comparing proton radiotherapy to photon radiotherapy, DAHANCA 35, we performed a non-randomized pilot study to investigate patient selection, logistics, planning, and treatment delivery. With the present study, as a comprehensive safety analysis, we want to compare toxicity during and up to two months after therapy to a historically matched group of patients treated with photon radiotherapy. MATERIALS AND METHODS: 62 patients treated with protons were matched to 124 patients who received photon treatment outside a protocol. Available data were retrieved from the DAHANCA database. Patients were matched on treatment centre, concurrent chemotherapy, tumour site, stage, p16 status for oropharynx cancers. Selection of patients for proton therapy was based on comparative treatment plans with a NTCP reduction for dysphagia and xerostomia at six months. RESULTS: Baseline characteristics between groups were well balanced, except for the type of drug used concurrently; more photon patients received Carboplatin (21.2 % vs 5.8 %, p = 0.01). Proton therapy was associated with significantly less weight loss at the end of treatment, mean weight loss of 3 % for protons and 5 % for photons (p < 0.001). There were more grade 3 skin reactions and grade 3 mucositis after proton treatment compared with photons at the end of treatment, Risk Ratio (RR) 1.9 (95 % CI: 1.01-3.5, p = 0.04) and RR 1.5 (95 % CI: 1.3-1.7, p < 0.001), respectively. All differences resolved at follow up two months after treatment. There were no significant differences between groups on opioid use, use of feeding tubes, or hospitalization during the observation period. CONCLUSION: Proton treatment resulted in excess objective mucositis and dermatitis, which was transient and did not seem to negatively influence weight or treatment compliance and intensity. Selection bias was likely especially since NTCP models were used for selection of proton treatment and photon treated patients were matched manually. We are currently including patients in a randomized controlled trial.
引用
- Nowicka-Matus K, Friborg J, Hansen CR, et al. Acute toxicities in proton therapy for head and neck cancer - A matched analysis of the DAHANCA 35 feasibility study. Clin Transl Radiat Oncol. 2024. PMID: 39189000. doi:10.1016/j.ctro.2024.100835
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。